Also, considering drug availability, cost-effectiveness, safety, tolerability, and genotype, current therapeutic guidelines [56, 59, 60] for hypercholesterolemia that start with statins with additions of other LLTs and are followed by PCSK9 inhibitors are still relevant, including for those with HoFH or compound heterozygous. This evidence concerns the gene PCSK9 and familial hypercholesterolemia.